Get 50% OFF This Summer!
Suraksha Diagnostic
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Suraksha Diagnostic Limited was incorporated as Suraksha Diagnostic Private Limited' as a private limited company dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata. Subsequently, Company was converted into a public limited company and the name of Company was changed to Suraksha Diagnostic Limited', and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre.
The Company is mainly engaged in running diagnostic centres for carrying out various pathological and radiological testing and medical consultation services in in East India. In addition to integrated pathology and radiology testing services, it also offer omnichannel medical consultation services via online and offline modes to customers through 43 of its diagnostic centres which house 120 polyclinic chambers hosting 750+ doctors. The diagnostic test menu included (a) 788 routine pathology tests ranging from basic biochemistry and hematology to 647 specialized pathology tests such as advanced biochemistry, histopathology, and molecular pathology, and (b) 748 basic/intermediate radiology tests ranging from basic x-rays, ultrasonography (USG), and computerized tomography (CT) scans to 104 advanced radiology tests such as magnetic resonance imaging (MRI) scans and specialized CT scans.
The first centre of the Company was launched at Kestopur in 2007. The second centre launched at Khardah in 2010, which increased the operating centres to 5. The Company increased the laboratories to 4 and the operating centres rose to 25 in 2016. The Company further acquired the business of Sunwell Diagnostic Private Limited in 2017. The operations to Meghalaya were expanded through a public-private partnership with the Government of Meghalaya in 2019. Further, 2 pre-existing diagnostic centres in Kolkata were acquired by the Company from Future Medical and Research Trust in 2020. And the first 3T MRI and 128 CT launched at New Town in 2023.
The Company is planning the Public Issue upto 19,189,330 Equity Shares through Offer for Sale.
Suraksha Diagnostic share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Suraksha Diagnostic indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Suraksha Diagnostic is valued compared to its competitors.
Suraksha Diagnostic PE ratio helps investors understand what is the market value of each stock compared to Suraksha Diagnostic 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Suraksha Diagnostic evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Suraksha Diagnostic generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Suraksha Diagnostic in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Suraksha Diagnostic shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Suraksha Diagnostic compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Suraksha Diagnostic over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Suraksha Diagnostic helps investors get an insight into when they can enter or exit the stock. Key components of Suraksha Diagnostic Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Suraksha Diagnostic shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Suraksha Diagnostic ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Suraksha Diagnostic provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Suraksha Diagnostic highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Suraksha Diagnostic .
The balance sheet presents a snapshot of Suraksha Diagnostic ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App